Ruili Wei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ruili Wei has a total of 168 co-authors. Here are the top co-authors by number of shared publications:
Jin-Wei Cheng
Department of Ophthalmology, Changzheng Hospital, Second Military Medical University, Shanghai, China (mainland)
43 shared publicationsJi-Ping Cai
Department of Ophthalmology, Changzheng Hospital, Second Military Medical University, Shanghai, China (mainland)
32 shared publicationsYou Li
Second Military Medical University
31 shared publicationsXiao-Ye Ma
A Department of Ophthalmology , Shanghai Changzheng Hospital, Second Military Medical University , Shanghai , China
14 shared publicationsYa Shen
Department of Ophthalmology, Changzheng Hospital of Naval Medical University, Shanghai, China
14 shared publicationsYuqing Chen
Department of Ophthalmology, Changzheng Hospital of Naval Medical University
11 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1963967
Comparing teacher-made and AI-assisted teaching videos for thyroid eye disease: an exploratory study
Background: Thyroid eye disease (TED), together with its acute and vision-threatening complication, dysthyroid optic neuropathy (DON), requires timely diagnosis and intervention. The limited availability of specialists in orbital diseases poses a significant challenge to ophthalmology residency training. In this context, generative artificial intelligence (AI) has created new opportunities for medical education, though its effectiveness in ophthalmology training remains to be explored. Objective: This exploratory study aims to evaluate the effectiveness of generative artificial intelligence (AI) in ophthalmology education, focusing on TED domains. Methods: The 46 residents (28 general residents and 18 ophthalmology residents) were randomly assigned to either an AI-assisted or a teacher-made 5-min teaching video on TED. All participants then completed three tests through online questionnaire experiments, each consisting of 20-item clinical questions about TED. Test 1 served as a baseline assessment of disease knowledge, Test 2 was conducted 5 min after learning to evaluate short-term learning outcomes, along with a questionnaire survey about AI tools, and Test 3 was administered 1 week later to assess long-term learning outcome. Results: Viewing the AI-assisted video significantly improved test scores from baseline to 5 min (mean difference = 13.04; p = 0.004), but the improvement was not sustained at 1 week (mean difference = 7.61; p = 0.16). Completion time also decreased significantly from baseline to both 5 min (p = 0.009; GMR = 0.57) and 1 week (p < 0.001; GMR = 0.45). No significant differences were observed between the AI-assisted and teacher-made video groups across all assessments (all p > 0.05). Additionally, learning experience was positively correlated with learning outcome (r = 0.60; P < 0.001). Conclusion: Our findings suggested that the AI-assisted and teacher-made videos for TED education showed no statistically significant difference. However, substantial expert oversight was required, and the AI-assisted workflow did not reduce total production time in this study. Given the limited long-term retention, such AI-assisted videos may be better positioned as supplementary resources combined with human expertise.
- 21 October 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1963967
Open AccessComparing teacher-made and AI-assisted teaching videos for thyroid eye disease: an exploratory study
Background: Thyroid eye disease (TED), together with its acute and vision-threatening complication, dysthyroid optic neuropathy (DON), requires timely diagnosis and intervention. The limited availability of specialists in orbital diseases poses a significant challenge to ophthalmology residency training. In this context, generative artificial intelligence (AI) has created new opportunities for medical education, though its effectiveness in ophthalmology training remains to be explored. Objective: This exploratory study aims to evaluate the effectiveness of generative artificial intelligence (AI) in ophthalmology education, focusing on TED domains. Methods: The 46 residents (28 general residents and 18 ophthalmology residents) were randomly assigned to either an AI-assisted or a teacher-made 5-min teaching video on TED. All participants then completed three tests through online questionnaire experiments, each consisting of 20-item clinical questions about TED. Test 1 served as a baseline assessment of disease knowledge, Test 2 was conducted 5 min after learning to evaluate short-term learning outcomes, along with a questionnaire survey about AI tools, and Test 3 was administered 1 week later to assess long-term learning outcome. Results: Viewing the AI-assisted video significantly improved test scores from baseline to 5 min (mean difference = 13.04; p = 0.004), but the improvement was not sustained at 1 week (mean difference = 7.61; p = 0.16). Completion time also decreased significantly from baseline to both 5 min (p = 0.009; GMR = 0.57) and 1 week (p < 0.001; GMR = 0.45). No significant differences were observed between the AI-assisted and teacher-made video groups across all assessments (all p > 0.05). Additionally, learning experience was positively correlated with learning outcome (r = 0.60; P < 0.001). Conclusion: Our findings suggested that the AI-assisted and teacher-made videos for TED education showed no statistically significant difference. However, substantial expert oversight was required, and the AI-assisted workflow did not reduce total production time in this study. Given the limited long-term retention, such AI-assisted videos may be better positioned as supplementary resources combined with human expertise.
- Open Access
- 20 July 2026
- Published by Springer Nature in Nano-Micro Letters
- Vol. 18 (1)
A Universal Bio-Hybrid Nanoparticle Backpack Platform Endows Stem Cells with Microenvironmental Resilience and Sustained Paracrine Signaling
The therapeutic potential of mesenchymal stem cells (MSCs) in regenerative medicine is frequently thwarted by hostile post-injury microenvironments characterized by oxidative stress, inflammation, and rapid clearance, which compromise cell survival and paracrine efficacy. Herein, we establish a universal bio-hybrid “stem cell backpack” platform designed to fundamentally overcome these bottlenecks through precise surface interface engineering. By tethering drug-loaded mesoporous silica nanoparticles onto the MSCs membrane via mild, biocompatible click chemistry, we create a programmable nanotherapeutic depot that endows host cells with dual, synergistic capabilities: (1) robust scavenging of reactive oxygen species (ROS) to ensure cellular resilience and (2) sustained, localized release of regenerative factors to amplify paracrine signaling. Using corneal chemical injury as a rigorous proof-of-concept model, this platform demonstrated unprecedented regenerative potency. The engineered cells markedly outperformed conventional therapies by simultaneously suppressing inflammatory cascades, preventing fibrosis and neovascularization, and orchestrating multi-lineage regeneration, including epithelial restoration, nerve reinnervation, and limbal stem cell reactivation. Quantitatively, this approach achieved a 63.6% enhancement in transparency restoration and a 76.9% greater reduction in tissue defects compared to cell monotherapy. Crucially, the modular design of this backpack system allows for the interchangeable loading of diverse therapeutics, extending its applicability beyond ophthalmology to other tissues facing similar microenvironmental challenges. This work presents a transformative paradigm in nanomedicine, shifting the focus from passive cell delivery to active microenvironmental modulation, thereby offering a versatile and scalable strategy for next-generation regenerative therapies across diverse clinical indications.
- 20 July 2026
- Published by Springer Nature in Nano-Micro Letters
- Vol. 18 (1)
Open AccessA Universal Bio-Hybrid Nanoparticle Backpack Platform Endows Stem Cells with Microenvironmental Resilience and Sustained Paracrine Signaling
The therapeutic potential of mesenchymal stem cells (MSCs) in regenerative medicine is frequently thwarted by hostile post-injury microenvironments characterized by oxidative stress, inflammation, and rapid clearance, which compromise cell survival and paracrine efficacy. Herein, we establish a universal bio-hybrid “stem cell backpack” platform designed to fundamentally overcome these bottlenecks through precise surface interface engineering. By tethering drug-loaded mesoporous silica nanoparticles onto the MSCs membrane via mild, biocompatible click chemistry, we create a programmable nanotherapeutic depot that endows host cells with dual, synergistic capabilities: (1) robust scavenging of reactive oxygen species (ROS) to ensure cellular resilience and (2) sustained, localized release of regenerative factors to amplify paracrine signaling. Using corneal chemical injury as a rigorous proof-of-concept model, this platform demonstrated unprecedented regenerative potency. The engineered cells markedly outperformed conventional therapies by simultaneously suppressing inflammatory cascades, preventing fibrosis and neovascularization, and orchestrating multi-lineage regeneration, including epithelial restoration, nerve reinnervation, and limbal stem cell reactivation. Quantitatively, this approach achieved a 63.6% enhancement in transparency restoration and a 76.9% greater reduction in tissue defects compared to cell monotherapy. Crucially, the modular design of this backpack system allows for the interchangeable loading of diverse therapeutics, extending its applicability beyond ophthalmology to other tissues facing similar microenvironmental challenges. This work presents a transformative paradigm in nanomedicine, shifting the focus from passive cell delivery to active microenvironmental modulation, thereby offering a versatile and scalable strategy for next-generation regenerative therapies across diverse clinical indications.
- Open Access
- 22 June 2026
- Published by Springer Nature in BMC Ophthalmology
- Vol. 26 (1)
Clinically accessible eye-tracking in thyroid-associated ophthalmopathy: exploratory classification modeling and gaze allocation to disease-related periocular images
Thyroid-associated ophthalmopathy (TAO) is an autoimmune orbital disease that may cause ocular motility abnormalities, altered periocular appearance, and psychosocial burden. However, clinically practical tools for early recognition and objective functional assessment remain limited. This study aimed to evaluate whether clinically accessible eye-tracking could support auxiliary classification of thyroid-associated ophthalmopathy and characterize visual attention patterns toward disease-related periocular images. In this cross-sectional study, 229 adults from a tertiary ophthalmology center were enrolled, including 181 patients with TAO and 48 healthy controls. Eye movements were recorded using a clinically accessible eye-tracking system during fixation, smooth pursuit with nine-grid spatial analysis, and image-viewing tasks. Random forest models were developed using nine-grid smooth-pursuit gaze-distribution features. A primary model included eye-tracking features plus age and sex, while a secondary model assessed eye-tracking features after demographic adjustment. Group differences in gaze metrics and region-of-interest allocation were analyzed using regression-based methods. Fixation stability did not differ significantly between groups, but patients with TAO showed increased gaze dispersion. In smooth pursuit, the primary model achieved an AUC of 0.903, and the secondary model achieved an AUC of 0.778. In image-viewing tasks, gaze allocation differed between groups: compared with controls, patients with TAO paid less attention to more obvious pathological periocular features in earlier-stage images and more attention to near-recovery appearances in later-stage images. Distinct viewing patterns were also observed across preoperative and postoperative images from different surgical categories. Clinically accessible eye-tracking may provide behavioral markers for auxiliary TAO classification and reveal altered visual attention to TAO-related periocular appearance. Further validation in larger, independent cohorts is needed. ClinicalTrials.gov, NCT07381413. Prospectively registered.
- 22 June 2026
- Published by Springer Nature in BMC Ophthalmology
- Vol. 26 (1)
Open AccessClinically accessible eye-tracking in thyroid-associated ophthalmopathy: exploratory classification modeling and gaze allocation to disease-related periocular images
Thyroid-associated ophthalmopathy (TAO) is an autoimmune orbital disease that may cause ocular motility abnormalities, altered periocular appearance, and psychosocial burden. However, clinically practical tools for early recognition and objective functional assessment remain limited. This study aimed to evaluate whether clinically accessible eye-tracking could support auxiliary classification of thyroid-associated ophthalmopathy and characterize visual attention patterns toward disease-related periocular images. In this cross-sectional study, 229 adults from a tertiary ophthalmology center were enrolled, including 181 patients with TAO and 48 healthy controls. Eye movements were recorded using a clinically accessible eye-tracking system during fixation, smooth pursuit with nine-grid spatial analysis, and image-viewing tasks. Random forest models were developed using nine-grid smooth-pursuit gaze-distribution features. A primary model included eye-tracking features plus age and sex, while a secondary model assessed eye-tracking features after demographic adjustment. Group differences in gaze metrics and region-of-interest allocation were analyzed using regression-based methods. Fixation stability did not differ significantly between groups, but patients with TAO showed increased gaze dispersion. In smooth pursuit, the primary model achieved an AUC of 0.903, and the secondary model achieved an AUC of 0.778. In image-viewing tasks, gaze allocation differed between groups: compared with controls, patients with TAO paid less attention to more obvious pathological periocular features in earlier-stage images and more attention to near-recovery appearances in later-stage images. Distinct viewing patterns were also observed across preoperative and postoperative images from different surgical categories. Clinically accessible eye-tracking may provide behavioral markers for auxiliary TAO classification and reveal altered visual attention to TAO-related periocular appearance. Further validation in larger, independent cohorts is needed. ClinicalTrials.gov, NCT07381413. Prospectively registered.
- Open Access
- 4 May 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1811285
A combined model of BCVA, TRAb, and NLR predicts response to intravenous methylprednisolone in dysthyroid optic neuropathy
Background: High-dose intravenous methylprednisolone (HD-IVMP) is the first-line treatment for dysthyroid optic neuropathy (DON). However, a significant proportion of patients exhibit a poor response, risking irreversible vision loss when surgical decompression is delayed. Identifying reliable predictors for failure of HD-IVMP is crucial for optimizing treatment strategies. This retrospective study aimed to identify risk factors associated with a poor response to HD-IVMP in DON patients, develop a predictive model for clinical decision-making, and assist in determining the optimal timing of orbital decompression surgery. Methods: A retrospective cohort study was conducted involving 44 patients (44 eyes) diagnosed with DON and treated with HD-IVMP. Basic characteristics, clinical features, orbital computed tomography (CT) findings, and laboratory parameters were analyzed. Treatment response was defined as complete visual recovery without requiring surgical decompression within 6 months. Least absolute shrinkage and selection operator (LASSO) and multivariable logistic regression analyses were used to screen and identify independent predictive factors. The predictive performance of the model was evaluated by plotting the receiver operating characteristic (ROC) curve. Additionally, decision curve analysis (DCA), net reclassification index (NRI), integrated discrimination improvement (IDI), and bootstrap internal validation were used to evaluate the clinical utility of the model. Results: At the 6-month follow-up, 20 of the 44 (42.5%) eyes achieved complete visual recovery and consequently avoided surgical decompression. A multivariable analysis identified three independent predictors of non-response to HD-IVMP: poorer baseline best-corrected visual acuity (BCVA; odds ratio [OR] = 1.43, 95% CI: 1.05–1.95, p = 0.04), higher thyroid-stimulating hormone receptor antibody (TRAb) levels (95% CI: 1.02–2.61, p = 0.04), and elevated NLR (OR = 1.30, 95% CI: 1.04–1.63, p = 0.02). A combined predictive model integrating these factors demonstrated superior performance (AUC = 0.944) with a sensitivity of 88% and a specificity of 85%, exceeding any single predictor. The internal validation also confirmed the model’s robust clinical utility. Conclusion: This study establishes that baseline BCVA, TRAb, and NLR are significant and readily available risk factors for failure of HD-IVMP in DON. The developed combination model provides clinicians with a valuable tool for the early identification of patients who are unlikely to benefit from medical therapy alone, thereby facilitating timely surgical intervention to prevent permanent visual damage and improve overall management outcomes. External validation of this model is required in future prospective studies.
- 4 May 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1811285
Open AccessA combined model of BCVA, TRAb, and NLR predicts response to intravenous methylprednisolone in dysthyroid optic neuropathy
Background: High-dose intravenous methylprednisolone (HD-IVMP) is the first-line treatment for dysthyroid optic neuropathy (DON). However, a significant proportion of patients exhibit a poor response, risking irreversible vision loss when surgical decompression is delayed. Identifying reliable predictors for failure of HD-IVMP is crucial for optimizing treatment strategies. This retrospective study aimed to identify risk factors associated with a poor response to HD-IVMP in DON patients, develop a predictive model for clinical decision-making, and assist in determining the optimal timing of orbital decompression surgery. Methods: A retrospective cohort study was conducted involving 44 patients (44 eyes) diagnosed with DON and treated with HD-IVMP. Basic characteristics, clinical features, orbital computed tomography (CT) findings, and laboratory parameters were analyzed. Treatment response was defined as complete visual recovery without requiring surgical decompression within 6 months. Least absolute shrinkage and selection operator (LASSO) and multivariable logistic regression analyses were used to screen and identify independent predictive factors. The predictive performance of the model was evaluated by plotting the receiver operating characteristic (ROC) curve. Additionally, decision curve analysis (DCA), net reclassification index (NRI), integrated discrimination improvement (IDI), and bootstrap internal validation were used to evaluate the clinical utility of the model. Results: At the 6-month follow-up, 20 of the 44 (42.5%) eyes achieved complete visual recovery and consequently avoided surgical decompression. A multivariable analysis identified three independent predictors of non-response to HD-IVMP: poorer baseline best-corrected visual acuity (BCVA; odds ratio [OR] = 1.43, 95% CI: 1.05–1.95, p = 0.04), higher thyroid-stimulating hormone receptor antibody (TRAb) levels (95% CI: 1.02–2.61, p = 0.04), and elevated NLR (OR = 1.30, 95% CI: 1.04–1.63, p = 0.02). A combined predictive model integrating these factors demonstrated superior performance (AUC = 0.944) with a sensitivity of 88% and a specificity of 85%, exceeding any single predictor. The internal validation also confirmed the model’s robust clinical utility. Conclusion: This study establishes that baseline BCVA, TRAb, and NLR are significant and readily available risk factors for failure of HD-IVMP in DON. The developed combination model provides clinicians with a valuable tool for the early identification of patients who are unlikely to benefit from medical therapy alone, thereby facilitating timely surgical intervention to prevent permanent visual damage and improve overall management outcomes. External validation of this model is required in future prospective studies.
- Open Access
- 13 April 2026
- Published by Elsevier in Experimental Eye Research
- Vol. 268, 111022
Therapeutic exploitation of ferroptosis pathways in dry eye disease: Opportunities and challenges
- 13 April 2026
- Published by Elsevier in Experimental Eye Research
- Vol. 268, 111022
Open AccessTherapeutic exploitation of ferroptosis pathways in dry eye disease: Opportunities and challenges
- Open Access
- 20 March 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1805546
Teprotumumab N01 for thyroid eye disease in China: clinical outcomes and quantitative MRI correlations
Background: Teprotumumab is an IGF-1R–targeted therapy for thyroid eye disease (TED). In routine practice, response assessment remains challenging and standardized imaging biomarkers are lacking. Objective: To evaluate the real-world effectiveness of domestically produced teprotumumab N01 injection (SYCUME®) in Chinese patients with TED and to identify inferior rectus (IR)–focused quantitative MRI measures associated with changes in proptosis and disease activity. Methods: We conducted a retrospective real-world study of patients with active moderate-to-severe TED who completed a full course of teprotumumab N01 between March and December 2025. Orbital MRI was acquired before and after treatment. IR, lacrimal gland (LG), and orbital fat (OF) were obtained using ROI-based analysis on MAGiC (T1, T2, proton density) and IDEAL-IQ (fat fraction). MRI proptosis and coronal morphologic measures were quantified in 3D Slicer. Eye-level changes and associations between clinical outcomes and MRI parameter changes ( Δ , post minus pre) were analyzed using linear mixed-effects models with a subject-specific random intercept, with Benjamini–Hochberg adjustment for MRI parameters. Laboratory indices and GO-QOL were analyzed at the patient level. Results: Twenty-two patients (44 orbits) were analyzed. Hertel proptosis and CAS decreased after treatment (both p < 0.001). MRI proptosis decreased ( p < 0.001) with reductions in IR maximum coronal length and width (both p < 0.001). IR ADC decreased ( p = 0.010). Mapping metrics showed decreases in IR T1 and proton density (both p < 0.001), while IR T2 did not reach statistical significance. Fat fraction increased in IR and OF. In Δ analyses, ΔMRI proptosis was associated with ΔIR maximum coronal length and width, and ΔCAS was associated with ΔIR morphologic changes and ΔIR ADC, with additional associations involving selected LG and OF quantitative parameters after multiple-comparison adjustment. Thyroid hormone levels remained stable overall. Selected antibodies and IGF-1 changed significantly. GO-QOL improved (all p < 0.001). At the patient level, only Δ TRAb and ΔIGF-1 were associated with ΔCAS, and no laboratory change was associated with ΔGO-QOL. Conclusion: In this real-world Chinese cohort, teprotumumab N01 was associated with concordant clinical improvement and quantitative MRI changes. IR-focused morphologic measures and diffusion-derived ADC showed the most consistent associations with changes in proptosis and disease activity, supporting their further evaluation for treatment monitoring in TED.
- 20 March 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1805546
Open AccessTeprotumumab N01 for thyroid eye disease in China: clinical outcomes and quantitative MRI correlations
Background: Teprotumumab is an IGF-1R–targeted therapy for thyroid eye disease (TED). In routine practice, response assessment remains challenging and standardized imaging biomarkers are lacking. Objective: To evaluate the real-world effectiveness of domestically produced teprotumumab N01 injection (SYCUME®) in Chinese patients with TED and to identify inferior rectus (IR)–focused quantitative MRI measures associated with changes in proptosis and disease activity. Methods: We conducted a retrospective real-world study of patients with active moderate-to-severe TED who completed a full course of teprotumumab N01 between March and December 2025. Orbital MRI was acquired before and after treatment. IR, lacrimal gland (LG), and orbital fat (OF) were obtained using ROI-based analysis on MAGiC (T1, T2, proton density) and IDEAL-IQ (fat fraction). MRI proptosis and coronal morphologic measures were quantified in 3D Slicer. Eye-level changes and associations between clinical outcomes and MRI parameter changes ( Δ , post minus pre) were analyzed using linear mixed-effects models with a subject-specific random intercept, with Benjamini–Hochberg adjustment for MRI parameters. Laboratory indices and GO-QOL were analyzed at the patient level. Results: Twenty-two patients (44 orbits) were analyzed. Hertel proptosis and CAS decreased after treatment (both p < 0.001). MRI proptosis decreased ( p < 0.001) with reductions in IR maximum coronal length and width (both p < 0.001). IR ADC decreased ( p = 0.010). Mapping metrics showed decreases in IR T1 and proton density (both p < 0.001), while IR T2 did not reach statistical significance. Fat fraction increased in IR and OF. In Δ analyses, ΔMRI proptosis was associated with ΔIR maximum coronal length and width, and ΔCAS was associated with ΔIR morphologic changes and ΔIR ADC, with additional associations involving selected LG and OF quantitative parameters after multiple-comparison adjustment. Thyroid hormone levels remained stable overall. Selected antibodies and IGF-1 changed significantly. GO-QOL improved (all p < 0.001). At the patient level, only Δ TRAb and ΔIGF-1 were associated with ΔCAS, and no laboratory change was associated with ΔGO-QOL. Conclusion: In this real-world Chinese cohort, teprotumumab N01 was associated with concordant clinical improvement and quantitative MRI changes. IR-focused morphologic measures and diffusion-derived ADC showed the most consistent associations with changes in proptosis and disease activity, supporting their further evaluation for treatment monitoring in TED.
- Open Access
- 30 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1762376
Extracellular vesicles in Graves’ disease and Graves’ orbitopathy: immunoregulatory mechanisms, biomarkers, and therapeutic potentials
Graves’ disease (GD) is a common autoimmune thyroid disorder and is often accompanied by Graves’ orbitopathy (GO), an inflammatory eye disease that can significantly reduce the quality of patients’ life. Despite understanding of GD and GO has progressed, the mechanisms driving disease progression remain incompletely defined. Emerging evidence highlights extracellular vesicles (EVs), particularly exosomes, as important mediators of immune regulation and tissue remodeling in autoimmune disorders, including GD and GO. This review summarizes current knowledge of EVs biogenesis and molecular compositions, highlighting their contributions to GD and GO pathogenesis. We also discuss the diagnostic and prognostic potential of EV-associated miRNAs and proteins, and consider findings from other immune-mediated ocular diseases to place these observations in a broader immunopathological context. Overall, EVs appear to be actively involved in GD and GO and may serve as useful tools for disease monitoring and therapy development. Nonetheless, challenges such as methodological variability and limited functional validation remains. Standardized protocols and larger, multicenter studies are needed to support the clinical translation of EV-based approaches.
- 30 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1762376
Open AccessExtracellular vesicles in Graves’ disease and Graves’ orbitopathy: immunoregulatory mechanisms, biomarkers, and therapeutic potentials
Graves’ disease (GD) is a common autoimmune thyroid disorder and is often accompanied by Graves’ orbitopathy (GO), an inflammatory eye disease that can significantly reduce the quality of patients’ life. Despite understanding of GD and GO has progressed, the mechanisms driving disease progression remain incompletely defined. Emerging evidence highlights extracellular vesicles (EVs), particularly exosomes, as important mediators of immune regulation and tissue remodeling in autoimmune disorders, including GD and GO. This review summarizes current knowledge of EVs biogenesis and molecular compositions, highlighting their contributions to GD and GO pathogenesis. We also discuss the diagnostic and prognostic potential of EV-associated miRNAs and proteins, and consider findings from other immune-mediated ocular diseases to place these observations in a broader immunopathological context. Overall, EVs appear to be actively involved in GD and GO and may serve as useful tools for disease monitoring and therapy development. Nonetheless, challenges such as methodological variability and limited functional validation remains. Standardized protocols and larger, multicenter studies are needed to support the clinical translation of EV-based approaches.
- 30 July 2025
- Published by Elsevier in Experimental Eye Research
- Vol. 259, 110565
Reduced microRNA-5572 in thyroid eye disease orbital fibroblasts promotes fibrosis by targeting F2RL2
- 30 July 2025
- Published by Elsevier in Experimental Eye Research
- Vol. 259, 110565
Reduced microRNA-5572 in thyroid eye disease orbital fibroblasts promotes fibrosis by targeting F2RL2
- Open Access
- 30 June 2025
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 13, 1619150
Advances in immunotherapy for uveal melanoma: enhancing efficacy and overcoming resistance
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults, presenting a significant clinical challenge due to its high metastatic potential and limited response to conventional systemic therapies. While immunotherapy has transformed the treatment landscape for numerous cancers, its effectiveness in UM has been substantially limited, primarily due to the tumor’s distinct immune-evasive characteristics and a suppressive tumor microenvironment (TME). This review systematically examines the multiple mechanisms underlying immunotherapy resistance in UM, including low tumor mutational burden, immune checkpoint overexpression, metabolic adaptations, and the epigenetic silencing of immune-stimulatory genes. Additionally, we analyze emerging strategies aimed at modifying the TME to enhance immune recognition and response, which include targeting suppressive immune cell populations, addressing metabolic and hypoxic barriers, and utilizing epigenetic modulators to restore immune activation pathways. Furthermore, we highlight recent advances in identifying predictive biomarkers—such as genetic mutations (e.g., BAP1, MBD4), immune gene signatures, circulating tumor DNA, and protein-based blood markers—that may facilitate patient stratification and treatment selection. We also examine novel combination approaches that integrate immune checkpoint inhibitors with targeted therapies, radiation, metabolic interventions, or engineered cellular therapies, several of which have shown promising clinical potential in overcoming UM’s inherent resistance mechanisms. Despite persistent challenges, such as toxicity management and limited availability of large-scale trials due to UM’s rarity, the integration of multi-omics profiling, precision medicine frameworks, and adaptive trial designs presents new opportunities for therapeutic advancement. This review provides a translational perspective on enhancing immunotherapy efficacy in UM by addressing its unique biology and identifying future directions for clinical innovation.
- 30 June 2025
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 13, 1619150
Open AccessAdvances in immunotherapy for uveal melanoma: enhancing efficacy and overcoming resistance
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults, presenting a significant clinical challenge due to its high metastatic potential and limited response to conventional systemic therapies. While immunotherapy has transformed the treatment landscape for numerous cancers, its effectiveness in UM has been substantially limited, primarily due to the tumor’s distinct immune-evasive characteristics and a suppressive tumor microenvironment (TME). This review systematically examines the multiple mechanisms underlying immunotherapy resistance in UM, including low tumor mutational burden, immune checkpoint overexpression, metabolic adaptations, and the epigenetic silencing of immune-stimulatory genes. Additionally, we analyze emerging strategies aimed at modifying the TME to enhance immune recognition and response, which include targeting suppressive immune cell populations, addressing metabolic and hypoxic barriers, and utilizing epigenetic modulators to restore immune activation pathways. Furthermore, we highlight recent advances in identifying predictive biomarkers—such as genetic mutations (e.g., BAP1, MBD4), immune gene signatures, circulating tumor DNA, and protein-based blood markers—that may facilitate patient stratification and treatment selection. We also examine novel combination approaches that integrate immune checkpoint inhibitors with targeted therapies, radiation, metabolic interventions, or engineered cellular therapies, several of which have shown promising clinical potential in overcoming UM’s inherent resistance mechanisms. Despite persistent challenges, such as toxicity management and limited availability of large-scale trials due to UM’s rarity, the integration of multi-omics profiling, precision medicine frameworks, and adaptive trial designs presents new opportunities for therapeutic advancement. This review provides a translational perspective on enhancing immunotherapy efficacy in UM by addressing its unique biology and identifying future directions for clinical innovation.
- 27 June 2025
- Published by Springer Nature in International Ophthalmology
- Vol. 45 (1) , 1-7
The clinical outcomes of ultra-low-dose radiotherapy for primary conjunctival mucosa-associated lymphoid tissue lymphoma
Purpose To assess the treatment efficacy, long-term outcomes and ocular toxicity of ultra-low-dose radiotherapy (4 Gy) in managing conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma. Methods This study retrospectively analyzed 15 patients with conjunctival MALT lymphoma between 2020 and 2022, who received 4 Gy radiotherapy (RT) delivered in consecutive 2-Gy fractions. The long-term outcomes included response rate, response time, recurrences or progression, and RT-related toxic effects. Results fifteen patients (eight males, seven females) all had histopathologically confirmed MALT lymphoma, which localized within unilateral or bilateral conjunctiva. At a median follow-up of 30 months (range, 9–48), complete response (CR) was observed in 89% of cases (n = 13) and partial response (PR) in 11% (n = 2), with a median time to CR of 2 months (range 1–12). Neither local nor distant recurrences were observed, and no disease progression occurred. There was no acute toxic effect in patients after RT. Only three patients developed mild dry eyes as a late treatment toxicity. Conclusion Ultra-low-dose RT presented an outstanding therapeutic effect on conjunctival MALT lymphoma with acceptable toxicity. Further studies like randomized controlled clinical trials can provide more evidence for clinical management.
- 27 June 2025
- Published by Springer Nature in International Ophthalmology
- Vol. 45 (1) , 1-7
The clinical outcomes of ultra-low-dose radiotherapy for primary conjunctival mucosa-associated lymphoid tissue lymphoma
Purpose To assess the treatment efficacy, long-term outcomes and ocular toxicity of ultra-low-dose radiotherapy (4 Gy) in managing conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma. Methods This study retrospectively analyzed 15 patients with conjunctival MALT lymphoma between 2020 and 2022, who received 4 Gy radiotherapy (RT) delivered in consecutive 2-Gy fractions. The long-term outcomes included response rate, response time, recurrences or progression, and RT-related toxic effects. Results fifteen patients (eight males, seven females) all had histopathologically confirmed MALT lymphoma, which localized within unilateral or bilateral conjunctiva. At a median follow-up of 30 months (range, 9–48), complete response (CR) was observed in 89% of cases (n = 13) and partial response (PR) in 11% (n = 2), with a median time to CR of 2 months (range 1–12). Neither local nor distant recurrences were observed, and no disease progression occurred. There was no acute toxic effect in patients after RT. Only three patients developed mild dry eyes as a late treatment toxicity. Conclusion Ultra-low-dose RT presented an outstanding therapeutic effect on conjunctival MALT lymphoma with acceptable toxicity. Further studies like randomized controlled clinical trials can provide more evidence for clinical management.